Morepen Laboratories : Q1'FY27 Investor Presentations

About this update from Morepen Laboratories Limited

‌Building Today. Transforming Tomorrow.‌‌‌‌ Q1'FY27 Investor Presentation Advancing Chemistry. Creating Possibilities. Discovery. Development. Delivery. 1 ‌Q1 FY27 - A Quarter of Commercial Validation Rs. 575 Cr Highest Ever Quarterly Revenue 3x EBITDA Highest Ever Quarterly EBITDA- 3x YoY Rs. 825 Cr CDMO mandate enters commercial supplies 15%+ EBITDA Blended EBITDA improves Export +111% Prioritisation of the customer mix Medical Devices Maintain strong growth Commercial validation of the Morepen 2.0 strategy. 2 ‌Financial Performance Reflects Operating Leverage (YoY) +34% Rs. 575.31 Cr Revenue +207% Rs. 87.72 Cr EBITDA +394% Rs. 56.35 Cr PAT 15%+ EBITDA Margin 31% API Growth 19% Devices Growth Rs. 58 Cr Commercial CDMO Dispatches Performance driven by operational execution. 3 ‌From Commodity APIs to Innovation-led Manufacturing Old Morepen New Addition Commodiity API busiiness Innovation-led Commodiity priiciing CDMO Long-duration Quarterlly vollatiilliity Recurring Transactiion-based busiiness Predictable Vollatiille earniings Scalable Morepen 2.0 manufacturing Long-duration customer programs earnings operating platform Transitioning from APIs to strategic manufacturing. 4 ‌The CDMO Journey Has Entered Commercial Scale‌ Development Customer Audit Validation Order Received Commercial Production Commercial Dispatched Why This Is More Than Just One Order Long-duratiion customer programme Recurriing revenues Hiigher margiins Glloball Pllatform valliidatiion 5 ‌Operating Leverage Begins Rs. in Crores, except margin Revenue Q1'FY26 Q1'FY27 429.64 0 100 200 300 400 500 600 575.31 +34% EBITDA PAT Q1'FY26 Q1'FY27 0 10 20 30 40 50 60 EBITDA Margin Q1'FY26 6.65% 2.3X Q1'FY27 15.25% Q1'FY26 Q1'FY27 87.72 0 20 40 60 80 100 0 5 10 15 20 28.58 11.41 56.35 +207% +394% +111% Export Revenue Performance driven by operational execution. 6 ‌API Business Returns to Healthy Profitability‌ Core API franchise stabilising while CDMO becomes the next growth layer. 31% API Growth API Export Up 42% Healthy recovery in the base business Better product mix with customer priortisation Improved Profitability Better operating discipline and product mix Capacity Realignment Selective prioritisation. toward higher-value opportunities A stronger API base supports the transition to a higher-quality CDMO platform. 7 ‌Regulatory Track Record Global audit readiness GMP-compliant manufacturing ...

View stock analysis, news, and events for Morepen Laboratories Limited